Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ustekinumab plus prednisone for non-infectious severe uveitis (phase 2 proof-of-concept)
2018-002569-20Phase 2Terminated
- Sponsor
- Centre Hospitalier Universitaire Dijon Bourgogne
- Start
- Jul 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ustekinumab in uveitis, sponsored by Centre Hospitalier Universitaire Dijon Bourgogne. Primary endpoint: Primary composite remission/relapse endpoint. Started Jul 2018; status: terminated.
02
Drugs
ustekinumab
03
Conditions
uveitis
Beyond the preview
Go deeper on 2018-002569-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002569-20.